Table 3. Combination analyses of eNOS 894G>T, miR-499b A>G, and TNF-α-863C>A polymorphisms in Korean RPL patients and controls.
| Combined genotype | Controls (n = 50) | RPL patients (n = 53) | OR (95% CI) | P value | |
|---|---|---|---|---|---|
| eNOS/miR-449b/TNF-α | |||||
| GG/AA/CC | 18 (36.0) | 11 (20.8) | 1.00 | ||
| GG/AA/CA+AA | 9 (18.0) | 6 (11.3) | 1.09 (0.30–3.91) | 0.894 | |
| GG/AG+GG/CC | 15 (30.0) | 17 (32.1) | 1.85 (0.67–5.15) | 0.236 | |
| GG/AG+GG/CA+AA | 2 (4.0) | 9 (17.0) | 7.36 (1.34–40.55) | 0.022* | |
| GT+TT/AA/CC | 1 (2.0) | 4 (7.5) | 6.55 (0.65–66.35) | 0.112 | |
| GT+TT/AA/CA+AA | 2 (4.0) | 1 (1.9) | 0.82 (0.07–10.12) | 0.876 | |
| GT+TT/AG+GG/CC | 3 (6.0) | 2 (3.8) | 1.09 (0.16–7.59) | 0.930 | |
| GT+TT/AG+GG/CA+AA | 0 | 3 (5.7) | 11.26 (0.53–238.56) | 0.120 | |
| eNOS/miR-449b | |||||
| GG/AA | 27 (54.0) | 17 (32.1) | 1.00 | ||
| GG/AG+GG | 17 (34.0) | 26 (49.1) | 2.43 (1.03–5.75) | 0.043* | |
| GT+TT/AA | 3 (6.0) | 5 (9.4) | 2.65 (0.56–12.53) | 0.220 | |
| GT+TT/AG+GG | 3 (6.0) | 5 (9.4) | 2.65 (0.56–12.53) | 0.220 | |
| eNOS/TNF-α | |||||
| GG/CC | 33 (66.0) | 28 (52.8) | 1.00 | ||
| GG/CA+AA | 11 (22.0) | 15 (28.3) | 1.61 (0.64–4.06) | 0.316 | |
| GT+TT/CC | 4 (8.0) | 6 (11.3) | 1.77 (0.45–6.90) | 0.412 | |
| GT+TT/CA+AA | 2 (4.0) | 4 (7.5) | 2.36 (0.40–13.85) | 0.343 | |
| miR-449b/TNF-α | |||||
| AA/CC | 19 (38.0) | 15 (28.3) | 1.00 | ||
| AA/CA+AA | 11 (22.0) | 7 (13.2) | 0.81 (0.25–2.58) | 0.717 | |
| AG+GG/CC | 18 (36.0) | 19 (35.8) | 1.34 (0.53–3.41) | 0.543 | |
| AG+GG/CA+AA | 2 (4.0) | 12 (22.6) | 7.60 (1.47–39.29) | 0.016* | |
Values are presented as number (%) of cases.
eNOS = endothelial nitric oxide synthase, TNF = tumor necrosis factor, RPL = recurrent pregnancy loss, OR = odds ratio, CI = confidence interval.
*P < 0.05.